RPTX (Repare Therapeutics Inc. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by RPTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-28 | CAROL SCHAFER | Director | D | — | — |
| 2026-01-28 | ANN D RHOADS | Director | D | — | — |
| 2026-01-28 | Thomas Civik | Director | D | — | — |
| 2026-01-28 | Sandra Isabelle Barros Alves | SVP, Finance and CAO | D | — | — |
| 2026-01-28 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | D | — | — |
| 2025-04-29 | Sandra Isabelle Barros Alves | SVP, Finance and CAO | A | — | — |
| 2025-04-04 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-03-14 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sell | — | — |
| 2025-03-14 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sell | — | — |
| 2025-03-14 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2025-03-14 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-03-06 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-03-06 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-03-06 | Lloyd Mitchell Segal | PRESIDENT AND CEO | A | — | — |
| 2024-06-20 | Steven H Stein | Director | A | — | — |
| 2024-06-20 | Susan Molineaux | Director | A | — | — |
| 2024-06-20 | ANN D RHOADS | Director | A | — | — |
| 2024-06-20 | CAROL SCHAFER | Director | A | — | — |
| 2024-06-20 | Briggs Morrison | Director | A | — | — |
| 2024-06-20 | Samarth Kulkarni | Director | A | — | — |
| 2024-06-20 | David P Bonita | Director | A | — | — |
| 2024-06-20 | Thomas Civik | Director | A | — | — |
| 2024-04-01 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2024-04-01 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sell | — | — |
| 2024-04-01 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sell | — | — |
| 2024-04-01 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2024-03-27 | Lloyd Mitchell Segal | PRESIDENT AND CEO | Sell | — | — |
| 2024-03-27 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2024-03-27 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | Sell | — | — |
| 2024-03-27 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2024-03-05 | Steve Forte | EVP, CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-03-04 | Michael Zinda | EVP, CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2024-03-04 | Maria Koehler | EVP, CHIEF MEDICAL OFFICER | A | — | — |
| 2024-03-04 | Lloyd Mitchell Segal | PRESIDENT AND CEO | A | — | — |
| 2023-12-12 | Maria Koehler | EVP, Chief Medical Officer | M | — | — |
| 2023-11-17 | BIOTECHNOLOGY VALUE FUND L P | 10%+ Owner | Buy | — | — |
| 2023-11-03 | BIOTECHNOLOGY VALUE FUND II LP | — | Buy | — | — |
| 2023-06-12 | Briggs Morrison | Director | A | — | — |
| 2023-06-12 | David P Bonita | Director | A | — | — |
| 2023-06-12 | Thomas Civik | Director | A | — | — |
| 2023-06-12 | Todd Foley | Director | A | — | — |
| 2023-06-12 | Susan Molineaux | Director | A | — | — |
| 2023-06-12 | CAROL SCHAFER | Director | A | — | — |
| 2023-06-12 | Samarth Kulkarni | Director | A | — | — |
| 2023-06-12 | ANN D RHOADS | Director | A | — | — |
| 2023-06-09 | Michael Zinda | EVP, Chief Scientific Officer | Sell | — | — |
| 2023-06-07 | Michael Zinda | EVP, Chief Scientific Officer | Sell | — | — |
| 2023-02-01 | Lloyd Mitchell Segal | President and CEO | A | — | — |
| 2023-02-01 | Steve Forte | EVP, Chief Financial Officer | A | — | — |
| 2023-02-01 | Maria Koehler | EVP, Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,940,497 | — |
| — | — | 3,792,157 | — |
| — | 10%+ Owner | 3,350,950 | — |
| — | — | 3,299,906 | — |
| — | Director | 3,221,637 | — |
| — | Director | 3,177,041 | — |
| — | 10%+ Owner | 2,977,733 | — |
| — | 10%+ Owner | 2,969,742 | — |
| — | 10%+ Owner | 2,825,662 | — |
| — | 10%+ Owner | 2,594,451 | — |
| — | 10%+ Owner | 2,344,451 | — |
| — | Director | 2,268,195 | — |
| — | 10%+ Owner | 1,801,581 | — |
| — | 10%+ Owner | 1,586,174 | — |
| — | 10%+ Owner | 548,938 | — |
| — | PRESIDENT AND CEO | 231,952 | — |
| — | 10%+ Owner | 231,211 | — |
| — | EVP, CHIEF MEDICAL OFFICER | 227,813 | — |
| — | 10%+ Owner | 144,879 | — |
| — | Director | 97,293 | — |
| — | Director | 96,216 | — |
| — | EVP, CHIEF SCIENTIFIC OFFICER | 80,297 | — |
| — | 10%+ Owner | 65,472 | — |
| — | 10%+ Owner | 63,619 | — |
| — | Director | 22,117 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RPTX quote page; the site-wide leaderboard is on the insider transactions hub.